Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M124,374Revenue $M20,063Net Margin (%)27.7Altman Z-Score2.8
Enterprise Value $M127,597EPS $6.7Operating Margin %33.3Piotroski F-Score5
P/E(ttm)22.1Beneish M-Score-2.7Pre-tax Margin (%)30.4Higher ROA y-yN
Price/Book4.710-y EBITDA Growth Rate %11.2Quick Ratio5.1Cash flow > EarningsY
Price/Sales6.15-y EBITDA Growth Rate %10.4Current Ratio5.5Lower Leverage y-yY
Price/Free Cash Flow16.2y-y EBITDA Growth Rate %21.8ROA % (ttm)8.3Higher Current Ratio y-yY
Dividend Yield %1.7PEG2.1ROE % (ttm)22.9Less Shares Outstanding y-yN
Payout Ratio %35.0Shares Outstanding M760ROIC % (ttm)20.1Gross Margin Increase y-yN

Gurus Latest Trades with AMGN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AMGNJoel Greenblatt 2015-03-31 Add0.37%$150.01 - $170.1
($157.49)
$ 163.584%Add 2874.44%309,134
AMGNFirst Eagle Investment 2015-03-31 Reduce-0.06%$150.01 - $170.1
($157.49)
$ 163.584%Reduce 23.66%497,622
AMGNDodge & Cox 2015-03-31 Reduce$150.01 - $170.1
($157.49)
$ 163.584%Reduce 17.65%54,704
AMGNMario Gabelli 2015-03-31 Add$150.01 - $170.1
($157.49)
$ 163.584%Add 1.23%39,985
AMGNKen Fisher 2015-03-31 Add$150.01 - $170.1
($157.49)
$ 163.584%Add 1.41%156,623
AMGNVanguard Health Care Fund 2014-12-31 Reduce-0.51%$130.45 - $171.64
($155.84)
$ 163.585%Reduce 20.54%5,580,485
AMGNMario Gabelli 2014-12-31 Reduce-0.02%$130.45 - $171.64
($155.84)
$ 163.585%Reduce 34.11%39,500
AMGNJoel Greenblatt 2014-12-31 Add0.01%$130.45 - $171.64
($156.25)
$ 163.585%Add 285.93%10,393
AMGNVanguard Health Care Fund 2014-09-30 Reduce-0.32%$115.39 - $144.01
($130.57)
$ 163.5825%Reduce 12.75%7,022,755
AMGNFirst Eagle Investment 2014-09-30 Buy 0.25%$115.39 - $144.01
($130.57)
$ 163.5825%New holding714,178
AMGNKen Fisher 2014-09-30 Add0.02%$115.39 - $144.01
($130.57)
$ 163.5825%Add 83.59%156,629
AMGNJoel Greenblatt 2014-09-30 Reduce-0.01%$115.39 - $144.01
($130.57)
$ 163.5825%Reduce 72.90%2,693
AMGNRuane Cunniff 2014-09-30 Buy $115.39 - $144.01
($130.57)
$ 163.5825%New holding1,617
AMGNVanguard Health Care Fund 2014-06-30 Reduce-0.06%$110.29 - $126.07
($115.88)
$ 163.5841%Reduce 2.00%8,049,455
AMGNMario Gabelli 2014-06-30 Add0.02%$110.29 - $126.07
($115.72)
$ 163.5841%Add 85.28%60,335
AMGNJoel Greenblatt 2014-06-30 Buy 0.02%$110.29 - $126.07
($115.72)
$ 163.5841%New holding9,938
AMGNKen Fisher 2014-06-30 Add0.01%$110.29 - $126.07
($115.72)
$ 163.5841%Add 71.02%85,316
AMGNDodge & Cox 2014-06-30 Reduce$110.29 - $126.07
($115.88)
$ 163.5841%Reduce 18.82%85,857
AMGNVanguard Health Care Fund 2014-03-31 Reduce-0.2%$113.48 - $127.47
($120.95)
$ 163.5835%Reduce 6.40%8,213,855
AMGNJoel Greenblatt 2014-03-31 Sold Out -0.06%$113.48 - $127.47
($121.04)
$ 163.5835%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AMGN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


AMGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Balachandran MadhavanEVP, Operations 2015-05-07Sell21,750$157.873.62view
Tross Stuart ASVP, Human Resources 2015-04-23Sell3,012$169.31-3.38view
Harper Sean EEVP, Research & Development 2015-04-22Sell28,000$171.58-4.66view
Tross Stuart ASVP, Human Resources 2015-03-03Sell4,415$157.743.7view
BALTIMORE DAVIDDirector 2015-03-02Sell3,647$158.763.04view
Bradway Robert AChairman, CEO and President 2015-02-11Sell22,000$152.697.13view
HERRINGER FRANK CDirector 2015-02-05Buy3,000$152.297.41view
de Carbonnel FrancoisDirector 2014-12-03Sell3,000$168.01-2.64view
Harper Sean EEVP, Research & Development 2014-08-05Sell14,000$127.2928.51view
Patton Cynthia MSVP & CCO 2014-08-05Sell2,644$127.9727.83view

Press Releases about AMGN :

    Quarterly/Annual Reports about AMGN:

    News about AMGN:

    Articles On GuruFocus.com
    Crouching Tigers, Hidden Assets – Smead Capital Management Apr 30 2015 
    securities Apr 27 2015 
    Amgen Reports An Upbeat Q1 Earnings Apr 23 2015 
    Amgen Inc.’s First Quarter Earnings Preview – What Could Be In Store? Apr 20 2015 
    Amgen’s First Drug For Cardiovascular Disease Gets The Green Light Apr 17 2015 
    Vanguard Health Care Fund Comments on Amgen Inc Mar 27 2015 
    Vanguard Health Care Fund 2014 Annual Report Mar 27 2015 
    Biogen And Idec To Part Ways After Inventing Alzheimer's Drug Mar 27 2015 
    Cracking The Best Healthcare Dividend Stock Secrets Mar 02 2015 
    Third Point LLC: Fourth Quarter Letter To Investors Feb 13 2015 

    More From Other Websites
    The Most Loved Biotechs of Big Hedge Funds May 23 2015
    Amgen Ends Psoriasis-Drug Partnership With AstraZeneca May 22 2015
    Amgen ends partnership with AstraZeneca on psoriasis drug May 22 2015
    Amgen ends partnership with AstraZeneca on psoriasis drug May 22 2015
    Amgen ends work on experimental psoriasis drug May 22 2015
    Amgen ends work on experimental psoriasis drug May 22 2015
    Amgen to terminate participation in co-development and commercialization of brodalumab May 22 2015
    Amgen ends collaboration with AstraZeneca on inflammation drug May 22 2015
    Amgen ends collaboration with AstraZeneca on inflammation drug May 22 2015
    AstraZeneca provides update on brodalumab development programme May 22 2015
    Amgen Ends Drug Pact With AstraZeneca After Signs of Suicide May 22 2015
    Amgen to terminate participation in co-development and commercialization of brodalumab May 22 2015
    A Beautiful Biotech Summer? May 22 2015
    Amgen Receives Positive CHMP Opinion For Use Of Repatha™ (Evolocumab) For The Treatment Of High... May 22 2015
    Amgen Receives Positive CHMP Opinion For Use Of Repatha™ (Evolocumab) For The Treatment Of High... May 22 2015
    7:31 am Amgen receives positive CHMP opinion for use of Repatha for the treatment of high... May 22 2015
    Amgen first to win EU backing for new kind of cholesterol drug May 22 2015
    Amgen first to win EU backing for new kind of cholesterol drug May 22 2015
    Billionaire Dan Loeb Slightly Shuffles Third Point’s Top Picks, Selling Off Large Alibaba Group... May 21 2015
    The 25 best healthcare companies to work for in America May 20 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK